Jeffrey:
With a bit of research and documentation, even given your narrow constraints, it would take hours to address your questions.
But I don't want to work within those constraints. First, I am concerned with the valuations of some companies that you might choose as comparisons. Second, you are asking me to ignore an issue, the tracking stock concern, that has been raised but not effectively rebutted.
So, you go first..... I challenge you to paint the bull case so clearly for us that I have no choice but to work within your constraints.
And then we'll all waltz to the bank. Until then, the market is clearly saying that it doesn't think that this new liquiditity should be labeled "priority, Genzyme".
The case for a new level of sector liquidity, moving forward, is strong, and I understand your urgency with respect to understanding the discrepancies in valuation.
I agree with rkrw, BTW.
|
